Gem Aromatics IPO GMP Today

GMP for Gem Aromatics IPO started at Rs 0 on 13 August 2025 and stood at Rs 26 on 22 August 2025. The sharpest single-day jump was from Rs 0 on 14 Aug 2025 to Rs 41 on 15 Aug 2025. The upward move through the subscription window usually reflects building demand across investor categories rather than a one-day spike.

Based on today's GMP, Gem Aromatics IPO listing price estimate is Rs 358.00 per share (issue price Rs 325.00 + GMP Rs 33.00).

Actual listing price will be known on 26 August 2025 when the stock lists on NSE/BSE.

At about 10.2% GMP, demand looks positive but not aggressive. Listing outcome will depend heavily on subscription data and market mood on listing day.

GMP has moved up over the tracked period. Steady increases through the subscription window are usually a stronger signal than a single-day spike.

GMP is unofficial. Listing gain can differ on listing day.

GMP and subscription numbers often move together. When institutional and HNI demand is strong, grey market participants usually price in a higher premium. Current overall subscription for Gem Aromatics IPO is 30.45x. Compare this with the GMP trend to see if demand aligns. The GMP move around 15 Aug 2025 may reflect how the market reacted once the subscription window activity picked up after 19 Aug 2025.

See live figures on the Gem Aromatics IPO Subscription Status page.

Gem Aromatics IPO full details (financials, peers, review).

Gem Aromatics Limited, established in 1997, is a leading manufacturer of specialty ingredients, including essential oils, aroma chemicals, and value-added derivatives. The company's products are used in a wide range of industries such as oral care, cosmetics, nutraceuticals, pharmaceuticals, personal care, and wellness. Gem Aromatics offers 70 products across four categories: mint and mint derivatives, clove and clove derivatives, phenol, and other synthetic and natural ingredients. The company serves domestic and global customers, including prominent names like Colgate-Palmolive, Dabur India, Patanjali Ayurved, and Symrise. It operates three manufacturing facilities in Uttar Pradesh, Dadra and Nagar Haveli, and Gujarat, supported by an in-house R&D facility in Maharashtra with a team of 13 scientists.